Mitochondrial dysfunction and Parkinson's disease genes: insights from Drosophila

被引:55
|
作者
Park, Jeehye [1 ,2 ]
Kim, Yongsung [1 ,2 ]
Chung, Jongkyeong [1 ,2 ,3 ]
机构
[1] Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Cell Growth Regulat, Taejon 305701, South Korea
[2] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea
[3] Korea Adv Inst Sci & Technol, Grad Sch Nanosci & Technol WCU, Taejon 305701, South Korea
关键词
SYNUCLEIN TRANSGENIC MICE; LOSS-OF-FUNCTION; DOPAMINERGIC-NEURONS; OXIDATIVE STRESS; DJ-1; MUTANTS; LIFE-SPAN; PINK1; MUTATIONS; DEGENERATION; PATHOLOGY;
D O I
10.1242/dmm.003178
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Parkinson's disease (PD), one of the most common neurodegenerative disorders worldwide, currently lacks a cure. Although most PD cases occur sporadically, studies from rare genetic mutations give significant insights into addressing the pathological mechanism of not only familial PD, but also sporadic PD. Recent PD research focuses on generating genetic mutant animal models that recapitulate the features of human PD patients. Significant advances in PD research have resulted from studying Drosophila mutants of several identified PD-associated genes because they show strikingly visible phenotypes. In particular, previous studies with the Drosophila mutants parkin and PINK1, which are two common causative genes among PD familial forms, have suggested strongly that mitochondrial dysfunction is the prominent cause for the PD pathogenesis and that these two PD genes are in a common pathway, with Parkin downstream of PINK1. Recent genetic studies have revealed that the PINK1-Parkin pathway is involved in regulating the mitochondrial remodeling process. In addition, PINK1 was recently found to regulate the localization of Parkin through direct phosphorylation. Here, we briefly review these new and exciting findings in Drosophila PD models and discuss how using these models can further advance PD studies.
引用
收藏
页码:336 / 340
页数:5
相关论文
共 50 条
  • [41] Mitochondrial dysfunction and oxidative stress in Parkinson's disease
    Hattori, N
    Tanaka, M
    Mizuno, Y
    JOURNAL OF NEUROCHEMISTRY, 1996, 67 : S33 - S33
  • [42] The genetic architecture of mitochondrial dysfunction in Parkinson's disease
    Larsen, S. B.
    Hanss, Z.
    Krueger, R.
    CELL AND TISSUE RESEARCH, 2018, 373 (01) : 21 - 37
  • [43] Ameliorating Mitochondrial Dysfunction for the Therapy of Parkinson's Disease
    Zheng, Qing
    Liu, Hanghang
    Gao, Yifan
    Cao, Guozhi
    Wang, Yusong
    Li, Zhen
    SMALL, 2024, 20 (29)
  • [44] Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease
    Ebadi, M
    Sharma, SK
    ANTIOXIDANTS & REDOX SIGNALING, 2003, 5 (03) : 319 - 335
  • [45] The genetic architecture of mitochondrial dysfunction in Parkinson’s disease
    S. B. Larsen
    Z. Hanss
    R. Krüger
    Cell and Tissue Research, 2018, 373 : 21 - 37
  • [46] Mitochondrial Dysfunction in Astrocytes: A Role in Parkinson's Disease?
    Bantle, Collin M.
    Hirst, Warren D.
    Weihofen, Andreas
    Shlevkov, Evgeny
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 8
  • [47] Mitochondrial dysfunction in Parkinson's disease: Is it the earliest feature?
    Murray, C. E.
    Pressey, S. N.
    Heywood, W. E.
    Hargreaves, I. P.
    Neergheen, V.
    Wauters, S.
    Palkovits, M.
    Gelpi, E.
    Troakes, C.
    Gentleman, S. M.
    Mills, K.
    Holton, J. L.
    Revesz, T.
    Gandhi, S.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2015, 41 : 11 - 11
  • [48] Mitochondrial dysfunction – a pathogenetic factor in Parkinson’s disease
    H. Reichmann
    B. Janetzky
    Journal of Neurology, 2000, 247 (Suppl 2) : II63 - II68
  • [49] Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease
    Beal, M. F.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S7 - S7
  • [50] Mitochondrial dysfunction and oxidative stress in Parkinson's disease
    Onyango, Isaac G.
    NEUROCHEMICAL RESEARCH, 2008, 33 (03) : 589 - 597